Article

Essilor's part in KBco

Essilor of America Inc. (EOA) has acquired a majority stake in KBco, one of the leading distributors of polarized lenses in the United States. KBco will operate as an independent subsidiary of EOA.

Dallas-Essilor of America Inc. (EOA) has acquired a majority stake in KBco, one of the leading distributors of polarized lenses in the United States. KBco will operate as an independent subsidiary of EOA. Its current management team will remain in place, including Kurt Hollinger, president, and John Olsen, chief operating officer.

"This acquisition will allow Essilor to expand our presence in the polarized segment of the industry. It will enhance our portfolio of products to support our customer base," said John Carrier, president of EOA. "KBco will continue with business as usual. We will work with Kurt Hollinger, John Olsen, and their management team to leverage Essilor's strength in product research and development, distribution, marketing, and financial resources."

"We believe that this acquisition will greatly benefit our customers and employees alike," said Hollinger. "Through this acquisition, Essilor and KBco will be able to utilize the strengths of both companies to help our customers build their businesses."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.